SCHEMBL15766377

SCHEMBL15766377

Oc1cc(-c2ccccc2)nc2c1sc1cc(F)ccc12

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 2/20 0.40
▸ LIMK1 P53667 3/20 0.38
▸ MAPT P10636 4/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ PPARA Q07869 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.36
▸ CREBBP Q92793 1/20 0.36
▸ ESR1 P03372 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ CCR6 P51684 1/20 0.36
▸ BCKDK O14874 1/20 0.36
▸ ALOX5 P09917 1/20 0.36
▸ TOP1 P11387 2/20 0.36
▸ THRB P10828 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15766176 0.85 CCR6 (0.42) DHODHLIMK1MAPTKDM4EPPARA
SCHEMBL15766605 0.84 MEN1 (0.41) DHODHLIMK1MAPTKDM4EPPARA
SCHEMBL15766147 0.75 BCKDK (0.36) LIMK1MAPTKDM4EBCKDKALOX5
SCHEMBL6667030 0.73 DHODH (0.54) DHODHKDM4EPDE10AESR1ESR2
SCHEMBL3625999 0.71 DHODH (0.62) DHODHMAPTKDM4EPDE10AESR1
SCHEMBL15766126 0.71 PRKCI (0.39) LIMK1MAPTKDM4EPPARACCR6
SCHEMBL15766405 0.70 BCKDK (0.39) MAPTKDM4EBCKDKHPGDSMN1; SMN2
SCHEMBL15766108 0.68 MEN1 (0.43) LIMK1MAPTKDM4EPPARAPDE10A
SCHEMBL10865346 0.67 AURKA (0.52) DHODHMAPTKDM4EPDE10AESR1
SCHEMBL6663164 0.67 DHODH (0.53) DHODHMAPTKDM4EPDE10AESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740734-B1 HCV PROTEASE INHIBITORS SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) 2017-09-06 — — EP disclosed
EP-2740734-B1 HCV PROTEASE INHIBITORS SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) 2017-09-06 — — EP disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
EP-2740734-A1 HCV PROTEASE INHIBITORS Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) 2014-06-11 — — EP disclosed
EP-2740734-A1 HCV PROTEASE INHIBITORS Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) 2014-06-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163219-A1 HCV Protease Inhibitors CPN1, CTRL, CTSZ DHODH 4447/4885LIMK1 3592/4885MAPT 4736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback